Prevention of neonatal group B streptococcal disease: Progress, challenges and dilemmas

Journal of Paediatrics and Child Health

Volumn 40, Issue 12, 2004, Pages 664-668

  Daley, Andrew J ^a   Garland, S M ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Group B streptococcus; Neonatal sepsis

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL POLYSACCHARIDE; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; PENICILLIN DERIVATIVE; PENICILLIN G; PEPTIDASE; STREPTOCOCCUS VACCINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATION; CLINICAL TRIAL; DRUG CHOICE; DRUG HYPERSENSITIVITY; DRUG UTILIZATION; ESCHERICHIA COLI; GESTATIONAL AGE; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; INFECTION RISK; MATERNAL DISEASE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN INFECTION; NEWBORN SEPSIS; PATIENT SELECTION; PERINATAL CARE; PERINATAL INFECTION; PRACTICE GUIDELINE; PREGNANCY; PREMATURITY; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; TECHNIQUE; VACCINATION; VAGINA SMEAR;

ANTI-BACTERIAL AGENTS; AUSTRALIA; CARRIER STATE; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PREGNANCY; SEPSIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; TIME FACTORS;

EID: 10644275155     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2004.00507.x     Document Type: Review

References (44)

1. Lancefield RC, Hare R. The serological differentiation of pathogenic and nonpathogenic strains of hemolytic streptococci from parturient women. J. Exp. Med. 1935; 61: 335-49.
2. Fry RM. Fatal infections by haemolytic streptococcus group B. Lancet 1938; 1: 199-201.
3. Hill AM, Butler HM. Haemolytic streptococcal infections following childbirth and abortion. 11 clinical features with special reference to infections due to streptococci of groups other than A. Med. J. Aust. 1940; 1: 293-9.
4. Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant infections. J. Pediatr. 1973; 82: 707-18.
5. Garland SM. Early onset neonatal group B streptococcus (GBS) infections: associated obstetric risk factors. Aust. NZ J. Obstet. Gynaecol. 1991; 31: 117-18.
6. Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N. Engl. J. Med. 1986; 314: 1665-9.
7. Garland SM, Fliegner JR. Group B streptococcus (GBS) and neonatal infections: the case for intrapartum chemoprophylaxis. Aust. NZ J. Obstet. Gynaecol. 1991; 31: 112-22.
8. Smaill F. Intrapartum antibiotics for group B streptococcal colonisation. Cochrane review. In: The Cochrane Library, Issue 2, Chichester, UK: John Wiley & Sons, Ltd, 2004.
9. Isaacs D, Royle JA. Intrapartum antibiotics and early onset neonatal sepsis caused by group B streptococcus and other organisms in Australia. Pediatr. Infect. Dis. J. 1999; 18: 524-8.
10. Jeffery HE, Lahra MM. Eight-year outcome of universal screening and intrapartum antibiotics for maternal group B streptococcal carriers. Pediatrics 1998; 101: e2.
11. Schrag SJ, Zywicki S, Farley MM et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N. Engl. J. Med. 2000; 342: 15-20.
12. Prevention of perinatal group B streptococcal disease: a public health perspective. Morb. Mortal Wkly Rep. 1996, 45[RR-7]: 1-24.
13. Schrag SJ, Zell ER, Lynfield R et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N. Engl. J. Med. 2002; 347: 233-9.
14. Prevention of perinatal group B streptococcal disease. Revised Guidelines from CDC. Morb. Mortal Wkly Rep. 2002; 51[RR-11]: 1-26.
15. Badri MS, Zawaneh S, Cruz AC et al. Rectal colonization with group B streptococcus: relation to vaginal colonization of pregnant women. J. Infect. Dis. 1977; 135: 308-12.
16. Quinlan JD, Hill DA, Maxwell BD, Boone S, Hoover F, Lense JJ. The necessity of both anorectal and vaginal cultures for group B streptococcus screening during pregnancy. J. Fam. Pract. 2000; 49: 447-8.
17. Gilbert GL, Hewitt MC, Turner CM, Leeder SR. Epidemiology and predictive values of risk factors for neonatal group B streptococcal sepsis. Aust. NZ J. Obstet. Gynaecol. 2002; 42: 497-503.
18. Molnar P, Biringer A, McGeer A, Mclsaac W. Can pregnant women obtain their own specimens for group B streptococcus? A comparison of maternal versus physician screening. Fam. Pract. 1997; 14: 403-6.
19. Mercer BM, Taylor MC, Fricke JL, Baselski VS, Sibai BM. The accuracy and patient preference for self-collected group B streptococcus cultures. Am. J. Obstet. Gynecol. 1995; 173: 1325-8.
20. Laboratory practices for prenatal group B streptococcal screening and reporting - Connecticut, Georgia, and Minnesota, 1997-98. Morb. Mortal Wkly Rep. 1999; 48: 426-8.
21. Kelly VN, Garland SM. Evaluation of new Granada medium (modified) for the antenatal screening of group B streptococcus. Pathology 1994; 26: 487-9.
22. Samadi R, Stek A, Greenspoon JS. Evaluation of a rapid optical immunoassay-based test for group B streptococcus colonization in intrapartum patients. J. Matern. Fetal Med. 2001; 10: 203-8.
23. Overman SB, Eley DD, Jacobs BE, Ribes JA. Evaluation of methods to increase the sensitivity and timeliness of detection of Streptococcus agalactiae in pregnant women. J. Clin. Microbiol. 2002; 40: 4329-31.
24. Bergeron MG, Ke D, Menard C et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl. J. Med. 2000; 343: 175-9.
25. Andrews JI, Diekema DJ, Hunter SK et al. Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. Am. J. Obstet. Gynecol. 2000; 183: 859-62.
26. Manning SD, Foxman B, Pierson CL, Tallman P, Baker CJ, Pearlman MD. Correlates of antibiotic-resistant group B streptococcus isolated from pregnant women. Obstet. Gynecol. 2003; 101: 74-9.
27. Stylianopoulos A, Kelly N, Garland S. Is penicillin and/or erythromycin resistance present in clinical isolates of group B streptococcus in our community? Aust. NZ J. Obstet. Gynaecol. 2002; 42: 543-4.
28. Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci to clindamycin and erythromycin. Obstet. Gynecol. 1998; 92: 258-61.
29. DeAzavedo JCS, McGavin M, Duncan C, Low DE, McGeer A. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob. Agents Chemother. 2001; 45: 3504-8.
30. Vermillion ST, Bland ML, Soper DE, Austin M. Antibiotic resistance patterns of group B streptococcus in late-third-trimester rectovaginal cultures. Obstet. Gynecol. 2000; 95: S79-80.
31. Stiver HG, Forward KR, Tyrrell DL et al. Comparative cervical microflora shifts after cefoxitin or cephazolin prophylaxis against infection following caesarean section. Am. J. Obstet. Gynecol. 1984; 149: 718-21.
32. Mercer BM, Carr TL, Beazley DD, Crouse DT, Sibai BM. Antibiotic use in pregnancy and drug-resistant infant sepsis. Am. J. Obstet. Gynecol. 1999; 181: 816-21.
33. Wendel GD Jr, Leveno KJ, Sanchez PJ, Jackson GL, McIntire DD, Siegel JD. Prevention of neonatal group B streptococcal disease: A combined intrapartum and neonatal protocol. Am. J. Obstet. Gynecol. 2002; 186: 618-26.
34. Reisner DP, Haas MJ, Zingheim RW, Williams MA, Luthy DA. Performance of a group B streptococcal prophylaxis protocol combining high-risk treatment and low-risk screening. Am. J. Obstet. Gynecol. 2000; 182: 1335-43.
35. Stoll BJ, Hansen N, Fanaroff AA et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N. Engl. J. Med. 2002; 347: 240-7.
36. Daley AJ, Isaacs D. Ten year study on the effect of intrapartum antibiotic prophylaxis on early-onset group B streptococcal and Escherichia coli neonatal sepsis in Australasia. Pediatr. Infect. Dis. J. 2004; 23: 630-4.
37. Davies HD, Raj S, Adair C, Robinson J, McGeer A. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. Pediatr. Infect. Dis. J. 2001; 20: 879-84.
38. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 1976; 294: 753-6.
39. Lin F-YC, Philips JB, Azimi PH et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J. Infect. Dis. 2001; 184: 1022-8.
40. Glezen WP. Alpers M. Maternal immunization. Clin. Infect. Dis. 1999; 28: 219-24.
41. Berner R. Group B streptococci during pregnancy and infancy. Curr. Opin. Infect. Dis. 2002; 15: 307-13.
42. Cheng QI, Carlson B, Pillai S et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect. Immun. 2001; 69: 2302-8.
43. Baker CJ, Paoletti LC, Wessels MR et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J. Infect. Dis. 1999; 179: 142-50.
44. Glaser P, Rusniok C, Buchrieser C et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Molec. Micro. 2002; 45: 1499-513.